Pulse Biosciences Inc (DE) (PLSE) Peer Comparison

$47.57

$-0.99 (-2.04%)

As on 28-Aug-2026 16:26EDT

Market cap

$3,393 Mln

Revenue (TTM)

$1 Mln

P/E Ratio

--

P/B Ratio

34.9

Div. Yield

0 %

Edit

	Pulse Biosciences Inc (DE) (PLSE)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Market cap ($ Mln)	3,393	12,753	10,906	10,222	9,762
Revenue ($ Mln)	1	1,505	613	785	2,589
Net Profit ($ Mln)	-80.06	160.59	-188.05	41.54	222.40
Net Margin (%)	-6,755.78	10.67	-30.68	5.29	8.59
RoE (%)	-88.87	10.86	-28.10	1.97	3.04
Price to Earnings	--	79.35	--	251.57	44.47
Price-To-Book	34.85	8.41	16.38	4.84	1.26

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Pulse Biosciences Inc (DE) (PLSE)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Operating Revenue	1.19	1,504.87	612.84	785.10	2,589.30
Cost of Revenue	1.44	483.98	127.96	384.30	1,245.50
Gross Profit	-1.26	942.44	393.22	347.62	1,343.60
Operating Expenses	82.79	833.56	565.37	335.50	1,108.90
Operating Profit (EBIT)	-83.04	187.34	-80.49	65.30	235.00
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	-80.06	203.83	-192.83	52.15	350.40
Provision for Tax	0.00	43.24	-4.79	10.61	128.00
Profit after Tax (Net Income)	-80.06	160.59	-188.05	41.54	222.40
Minority Interest	0.00	0.00	0.00	0.00	0.00
Consolidated Profit	0.00	93.19	0.00	0.00	0.00

Liabilities ($ Mln)

	Pulse Biosciences Inc (DE) (PLSE)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Shareholder's Funds	99.50	1,530.77	682.49	2,112.03	7,173.90
Minority Interest	0.00	0.00	0.00	0.00	0.00
Non-Current Liabilities	5.09	210.18	135.71	705.49	2,116.80
Current Liabilities	10.98	233.78	102.33	132.66	961.30
Total Liabilities	96.11	1,826.52	893.49	2,949.70	10,576.50

Assets ($ Mln)

	Pulse Biosciences Inc (DE) (PLSE)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Non-Current Assets	9.86	630.60	404.74	1,749.63	7,231.50
Current Assets	105.70	1,344.12	515.78	1,200.55	3,020.50
Total Assets	96.11	1,826.52	893.49	2,949.70	10,576.50
Total Debt*	6.77	212.71	102.84	690.94	1,203.70
Net Current Assets	94.72	1,110.35	413.45	1,067.90	2,059.20

Cashflow ($ Mln)

	Pulse Biosciences Inc (DE) (PLSE)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Cash From Operating Activities	-54.12	238.66	-46.34	117.42	532.20
Cash Flow from Investing Activities	-0.34	-404.59	-77.61	-298.47	-189.70
Cash from Financing Activities	17.15	26.53	11.89	-15.21	-283.20
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	Pulse Biosciences Inc (DE) (PLSE)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
ROCE (%)	-68.68	11.76	-22.53	1.79	8.98
ROE (%)	-88.87	10.86	-28.10	1.97	3.04
ROA (%)	-62.60	7.95	-18.00	1.36	2.02
EBIT Margin (%)	-4,723.04	13.63	-30.58	9.87	-5.99
Net Margin (%)	-6,755.78	10.67	-30.68	5.29	8.59
Cash Profit Margin (%)	-0.01	0.00	0.00	0.00	0.00

Growth Ratios

	Pulse Biosciences Inc (DE) (PLSE)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Revenue Growth (%)	-52.52	17.55	41.55	16.49	1.37
EBIT Growth (%)	17.73	17.49	-116.42	920.91	-131.06
Net Profit Growth (%)	-17.68	8.72	-102.66	400.42	-30.32
EPS Growth (%)	-9.50	8.12	-96.88	394.30	-29.66
Book Value Growth (%)	-7.42	17.33	-12.65	2.16	2.19

Valuation Ratios

	Pulse Biosciences Inc (DE) (PLSE)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Price / Earnings	-12.71	68.93	-34.59	189.42	--
Price / Book Value	11.47	8.58	9.90	4.40	--
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	-11.88	53.25	-43.50	55.90	--
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Pulse Biosciences Inc (DE) (PLSE)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Debt to Equity	0.00	0.00	0.00	0.26	0.11
Short term debt to equity ratio	0.02	0.01	0.00	0.01	0.06
Current Ratio	9.63	5.75	5.04	9.05	3.14
Quick Ratio	9.61	3.86	4.46	7.64	2.33
Interest Coverage	--	157.91	-38.31	3.36	8.18

Operating Efficiency Ratios

	Pulse Biosciences Inc (DE) (PLSE)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Debtors to sales (%)	10.30	12.65	22.67	20.09	17.06
Asset Turnover	0.01	0.74	0.59	0.26	0.24
Receivable days	142.97	46.54	60.95	72.41	65.39
Inventory Days	15.43	331.92	193.84	146.53	221.09
Payable days	504.77	26.16	60.19	29.05	37.02
Cash Conversion Cycle	-346.37	352.30	194.60	189.88	249.46

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly